pirenzepine has been researched along with Epilepsy in 2 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here we investigated the effect of the mAChR agonist carbachol (CCh) and various mAChR antagonists in human cortical slices (from tissue removed during neurosurgical treatment of epilepsy) by intracellular and extracellular recordings." | 3.78 | Muscarinic acetylcholine receptor-mediated effects in slices from human epileptogenic cortex. ( Dehnicke, C; Deisz, RA; Gigout, S; Horn, P; Lehmann, TN; Wierschke, S, 2012) |
| ", ip) indicate that the liver is the primary site of biotransformation of the compound, suggesting that both 22a and its metabolite(s) are active, compensating probably low bioavailability of the parent molecule." | 1.43 | Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents. ( Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Waszkielewicz, AM | 1 |
| Gunia-Krzyżak, A | 1 |
| Powroźnik, B | 1 |
| Słoczyńska, K | 1 |
| Pękala, E | 1 |
| Walczak, M | 1 |
| Bednarski, M | 1 |
| Żesławska, E | 1 |
| Nitek, W | 1 |
| Marona, H | 1 |
| Gigout, S | 1 |
| Wierschke, S | 1 |
| Lehmann, TN | 1 |
| Horn, P | 1 |
| Dehnicke, C | 1 |
| Deisz, RA | 1 |
2 other studies available for pirenzepine and Epilepsy
| Article | Year |
|---|---|
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Topics: Amino Alcohols; Animals; Anticonvulsants; Chemistry, Physical; Dose-Response Relationship, Drug; Dru | 2016 |
Muscarinic acetylcholine receptor-mediated effects in slices from human epileptogenic cortex.
Topics: Action Potentials; Adult; Biophysics; Carbachol; Cerebral Cortex; Cholinergic Agonists; Drug Combina | 2012 |